Stoke Therapeutics (NASDAQ:STOK) Shares Down 4.4% - Here's Why

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s share price dropped 4.4% during trading on Monday . The stock traded as low as $9.41 and last traded at $9.34. Approximately 209,894 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 712,493 shares. The stock had previously closed at $9.76.

Wall Street Analysts Forecast Growth

STOK has been the subject of several research analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. HC Wainwright reaffirmed a "buy" rating and set a $47.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Chardan Capital reissued a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Stoke Therapeutics currently has an average rating of "Buy" and a consensus target price of $24.67.

Stoke Therapeutics Stock Down 2.4 %

The stock has a market capitalization of $525.77 million, a PE ratio of -4.59 and a beta of 1.20. The business's fifty day moving average is $7.90 and its two-hundred day moving average is $10.18.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares of the company's stock, valued at $1,285,353.51. This trade represents a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock worth $143,332 over the last ninety days. Company insiders own 11.30% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds have recently bought and sold shares of the business. Toronto Dominion Bank bought a new stake in shares of Stoke Therapeutics during the fourth quarter worth $35,001,000. RTW Investments LP lifted its holdings in Stoke Therapeutics by 10.1% during the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after buying an additional 471,240 shares in the last quarter. Norges Bank purchased a new stake in Stoke Therapeutics in the 4th quarter valued at about $3,472,000. Tang Capital Management LLC bought a new position in Stoke Therapeutics in the 4th quarter worth about $3,309,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Stoke Therapeutics during the fourth quarter worth approximately $3,218,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.